[ad_1]
EDonanemab, Li Lilly’s investigational Alzheimer’s disease drug, has shown some of the best early results seen by pharmaceutical researchers in the field. What divides many researchers is whether this is a reason for excitement or not.
The results, published at the International Conference on Alzheimer’s and Parkinson’s Diseases on Saturday and published in the New England Journal of Medicine, come from a Phase 2 study, typically used by pharmaceutical companies to test whether a drug deserves to be tested in a larger phase 3 study which may lead to approval. Although the main findings were previously described in a press release from Lilly, they represent a strong watermark for studies of Alzheimer’s disease. This is the first time that a Phase 2 study of a drug that attempts to slow Alzheimer’s disease, and not just alleviate patients’ symptoms, has had a positive result.
Unlock this article by subscribing to STAT + and enjoy your first 30 days free!
TO START
What is that?
STAT + is STAT’s premium subscription service for in-depth coverage and analysis in biotechnology, pharmacy, policy and life sciences. Our award-winning team covers the news on Wall Street, political developments in Washington, early scientific breakthroughs and clinical trial results, and the disruption of healthcare in Silicon Valley and beyond.
What is included?
- Daily reports and analyzes
- The most comprehensive coverage in the industry by a team of powerful journalists
- Subscriber newsletters
- Daily newsletters to keep you informed about the most important news in the sector
- STAT + conversations
- Weekly opportunities to engage with our journalists and leading industry experts in live video chats
- Exclusive industry events
- Premium access to subscriber-only networking events nationwide
- The best reporters in the industry
- The most trusted and connected newsroom in the healthcare industry
- And much more
- Exclusive interviews with industry leaders, profiles and high-end tools, like our CRISPR Trackr.
[ad_2]
Source link